Protection of Lymphocytes Against HIV using Lentivirus Vector Carrying a Combination of <italic>TRIM5α-HRH</italic> Genes and microRNA Against <italic>CCR5</italic>.

Gene therapy is considered a promising approach to treating infections caused by human immunodeficiency virus (HIV). One strategy is to introduce antiviral genes into cells in order to impart resistance to HIV. In this work, the antiviral activity of new anti-HIV lentiviral vector <bold>pT</bold> has been studied. The vector carries a combination that consists of two identical artificial miRNA mic13lg and the <italic>TRIM5α-HRH</italic> gene. Two mic13lg microRNAs suppress the expression of the <italic>CCR5</italic> gene, which encodes the HIV coreceptor and, thus, prevents the penetration of R5-tropic HIV strains into the cell. It has been shown that pT effectively inhibits the expression of <italic>CCR5</italic> in both the HT1080 CCR5-EGFP model cell line and in human primary lymphocytes. The second line of protection against R5- and X4-tropic HIV is provided by the TRIM5α-HRH protein, which binds virus capsids after the virus enters the cell. Indeed, when infecting cells of the SupT1 line, which contains four copies of the vector per cell, with the X-4 tropic HIV, more than 1000-fold suppression of viral replication has been observed. The process of generation of the <bold>pT</bold> vector and conditions of transduction of CD4+ lymphocytes were optimized for testing the antiviral activity of the vector on primary human lymphocytes. As a result, the transduction efficiency for the <bold>pT</bold> vector was 28%. After infection with the R5-tropic strain of the virus, the survival of cells in the culture of lymphocytes with the vector was significantly higher than in the control. However, the complete suppression of HIV replication was not achieved, presumably due to the inadequate fraction of cells that carry the vector in culture. In the future, it is planned to find the best way to enrich the lymphocyte culture with modified cells to increase resistance to HIV. [ABSTRACT FROM AUTHOR]